GlassBury AI combines agentic patient matching with culturally sensitive community education to eliminate healthcare disparities. By pairing AI with expert-curated workshops, we build the trust necessary to connect underrepresented patients with life-changing clinical trials.
Combating Alzheimer's: Current Treatments and Promising Pipeline Drugs
Alzheimer's disease is a devastating neurodegenerative disorder that affects millions worldwide. As the global population ages, the prevalence of Alzheimer's and related dementias is expected to rise significantly.
Eliminating Bias in Pre-Screening: How Agentic AI Parses Unstructured EHR Notes for Alzheimer’s Research
Discover how Glassbury AI’s agentic architecture and zero-text FHIR mapping help biopharma sponsors achieve FDA Diversity Action Plan (DAP) compliance and eliminate Alzheimer’s trial screen failures.